A detailed history of Hbk Sorce Advisory LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hbk Sorce Advisory LLC holds 34,923 shares of BMY stock, worth $2.03 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
34,923
Previous 31,544 10.71%
Holding current value
$2.03 Million
Previous $1.31 Million 37.94%
% of portfolio
0.07%
Previous 0.05%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$39.66 - $51.75 $134,011 - $174,863
3,379 Added 10.71%
34,923 $1.81 Million
Q2 2024

Aug 08, 2024

SELL
$40.25 - $52.99 $41,618 - $54,791
-1,034 Reduced 3.17%
31,544 $1.31 Million
Q1 2024

May 09, 2024

BUY
$47.98 - $54.4 $55,608 - $63,049
1,159 Added 3.69%
32,578 $1.77 Million
Q4 2023

Jan 25, 2024

SELL
$48.48 - $57.85 $178,164 - $212,598
-3,675 Reduced 10.47%
31,419 $1.61 Million
Q3 2023

Nov 06, 2023

BUY
$57.89 - $64.73 $1,099 - $1,229
19 Added 0.05%
35,094 $2.04 Million
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $2.43 Million - $2.7 Million
-38,191 Reduced 52.13%
35,075 $2.24 Million
Q1 2023

Aug 15, 2023

BUY
$65.71 - $74.53 $228,802 - $259,513
3,482 Added 9.93%
38,557 $2.67 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $46,522 - $52,767
-708 Reduced 0.96%
73,266 $7.74 Million
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $2.76 Million - $3.26 Million
40,243 Added 119.31%
73,974 $5.32 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $709 - $419,469
5,459 Added 19.31%
33,731 $2.4 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $460,265 - $506,913
-6,338 Reduced 18.31%
28,272 $2.18 Million
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $20,288 - $24,327
-330 Reduced 0.94%
34,610 $2.53 Million
Q4 2021

Feb 15, 2022

SELL
$53.63 - $62.52 $1,662 - $1,938
-31 Reduced 0.09%
34,940 $2.18 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $112,127 - $131,342
-1,895 Reduced 5.14%
34,971 $2.07 Million
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $28,850 - $31,417
-466 Reduced 1.25%
36,866 $2.46 Million
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $31,390 - $35,305
529 Added 1.44%
37,332 $2.36 Million
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $3,753 - $4,252
-65 Reduced 0.18%
36,803 $2.28 Million
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $65,240 - $72,295
1,136 Added 3.18%
36,868 $2.22 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $432,529 - $505,670
7,890 Added 28.34%
35,732 $2.1 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $51,179 - $74,375
-1,103 Reduced 3.81%
27,842 $1.55 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $161,507 - $210,671
3,282 Added 12.79%
28,945 $1.86 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $55,472 - $65,770
-1,297 Reduced 4.81%
25,663 $1.3 Million
Q2 2019

Aug 15, 2019

BUY
$44.62 - $49.34 $627,669 - $694,065
14,067 Added 109.11%
26,960 $1.22 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $818,330 - $904,895
-18,340 Reduced 58.72%
12,893 $948,000
Q1 2019

May 13, 2019

BUY
$45.12 - $53.8 $450,884 - $537,623
9,993 Added 47.05%
31,233 $1.49 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $12,433 - $16,123
-255 Reduced 1.19%
21,240 $1.1 Million
Q3 2018

Nov 15, 2018

SELL
$55.19 - $62.25 $39,350 - $44,384
-713 Reduced 3.21%
21,495 $1.33 Million
Q2 2018

Aug 10, 2018

SELL
$50.53 - $62.98 $34,916 - $43,519
-691 Reduced 3.02%
22,208 $0
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $33,075 - $38,076
552 Added 2.47%
22,899 $1.45 Million
Q4 2017

Feb 15, 2018

BUY
$59.94 - $65.35 $301,378 - $328,579
5,028 Added 29.03%
22,347 $1.37 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $956,528 - $1.1 Million
17,319
17,319 $1.1 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hbk Sorce Advisory LLC Portfolio

Follow Hbk Sorce Advisory LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hbk Sorce Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hbk Sorce Advisory LLC with notifications on news.